Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus
| Autor: | Donald B Wiest, Y Brown, S Schall, Richard L Weaver, Peter S Gal, J Laurence Ransom, Dilip Purohit, Julianne B Pinson, Richard C. Brundage |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
medicine.medical_specialty Birth weight Indomethacin Population Gestational Age Population pharmacokinetics Gastroenterology Pharmacokinetics Internal medicine Ductus arteriosus medicine Birth Weight Humans Pharmacology (medical) education Ductus Arteriosus Patent Pharmacology Volume of distribution education.field_of_study business.industry Infant Newborn Gestational age Postnatal age medicine.anatomical_structure Anesthesia Injections Intravenous Linear Models Drug Evaluation Female business |
| Zdroj: | Clinical Pharmacology and Therapeutics. 49:550-557 |
| ISSN: | 1532-6535 0009-9236 |
| Popis: | The population pharmacokinetics of intravenous indomethacin were investigated with 665 indomethacin serum concentrations from 83 neonates (mean ± SD: gestational age, 28.8 ± 2.5 weeks; postnatal age, 5.7 ± 4.7 days; birth weight, 1.13 ± 0.40 kg) receiving indomethacin for symptomatic patent ductus arteriosus. A one-compartment open model was used for pharmacokinetic analysis. Hypotheses were tested to determine which developmental and demographic data influenced clearance (CL) and volume of distribution (Varea). In the final regression equation CL and Varea were modeled as a function of body weight and postnatal age (PNA) from 0 to 20 days. Final estimates were as follows: CL (ml/hr) = 2.63 · weight (kg) + 0.244 · PNA (days) and Varea (L) = 0.28 · weight (kg) + 0.0041 · PNA (days). The coefficients of variation for interindividual variability in CL and Varea were 77% and 28%, respectively. Intraindividual variability was 19%. These mean population parameter estimates should prove useful in designing dosage regimens to achieve desired indomethacin concentrations for neonates from 0 to 20 days of age with symptomatic patent ductus arteriosus. Clinical Pharmacology and Therapeutics (1991) 49, 550–557; doi:10.1038/clpt.1991.65 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text